Sun Pharmaceuticals Industries, a Rs. 52,500 crore plus Indian pharma leader, has posted consolidated net profit growth of only 2.5 per cent during the second quarter ended September 2025, mainly due to stagnant growth in US formulation sales, to Rs. 3,118 crore as against Rs. 3,041 crore in the corresponding period of last year. EPS of face value of Re.1 per share worked out to Rs. 13 as compared to Rs. 12.7 in the last period.
Sun Pharma’s consolidated revenue improved by 8.9 per cent to Rs. 14,478 crore from Rs. 13,291 crore. Other income increased to Rs. 470 crore from Rs. 354 crore in the last period. Its total formulation sales increased by 9.7 per cent to Rs. 13,942 crore from Rs. 12,708 crore. Indian formulation sales increased by 11 per cent to Rs. 4,735 crore from Rs. 4,265 crore. Indian formulation sales accounted for 32.9 per cent of total sales. Its sales in US remained stagnant at Rs. 4,329 crore as against Rs. 4,327 crore. The decline in generics business was offset by growth in innovative medicines. US sales accounted for approximately 30.1 per cent of total consolidated sales.
Its sales in Emerging Markets stood at Rs. 2,837 crore as compared to Rs. 2,452 crore and in Rest of the World improved by 22.7 per cent to Rs. 2,041 crore from Rs. 1,663 crore. However, APIs sales declined to Rs. 430 crore from Rs. 534 crore.
Kirti Ganorkar, managing director, said, “India, Emerging Markets and Rest of World led our growth for the period. US sales of innovative medicines have surpassed generics for the first time during the quarter. We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability.”
Sun Pharma’s R&D efforts span across both innovative and generic businesses and the company continues to invest in building the pipeline for various markets. The R&D spending remained at Rs. 789 crore during the quarter as compared to Rs. 793 crore in the last year. Sun’s innovative R&D pipeline includes six novel entities in clinical stage. Sun has a comprehensive product offering in the US market consisting of approved ANDAs for 548 products while filings for 117 ANDAs await US FDA approval, including 31 tentative approvals. During the quarter, 4 ANDAs were filed, and approval received for 5 ANDAs. Sun’s portfolio includes 57 approved NDAs while 14 NDAs await US FDA approval. 1 NDA was filed during the quarter.
For the first half ended September 2025, Sun Pharma’s consolidated revenue increased by 9.4 per cent to Rs. 28,330 crore from Rs. 25,944 crore in the corresponding period of last year. However, its net profit declined by 8.2 per cent to Rs. 5,396 crore from Rs. 5,876 crore. Its R&D expenditure increased to Rs. 1,686 crore from Rs. 1,587 crore. Indian revenues increased by 12.4 per cent to Rs. 9,456 crore from Rs. 8,410 crore and US formulation sales increased only by 2 per cent to Rs. 8,374 crore from Rs. 8,217 crore. For the full year ended March 2025, its consolidated revenue stood at Rs. 52,578 crore and posted net profit of Rs. 10,929 crore. |